Послать статью по эл. почте 
Открытый доступ
Только для подписчиков
Изолированная офисная гипертония (гипертония «белого халата») в клинике Медицины труда (аналитический обзор)
https://doi.org/10.31089/1026-9428-2018-10-33-38
Аннотация
Артериальная гипертония представляет значимую проблему при экспертизе профпригодности у работников, занятых на тяжелых работах и на работах с вредными и (или) опасными условиями труда. При принятии экспертных решений необходимо учитывать медицинские противопоказания, интерпретация которых может представлять определенные трудности в практической работе. Систематизированы литературные данные по диагностике и клинической значимости изолированной офисной артериальной гипертонии (АГ; гипертонии «белого халата»).
Об авторах
А. Е. НосовРоссия
Носов Александр Евгеньевич, зав. стационаром (отд. профпатологии терапевтического профиля) ФБУН «ФНЦ МПТ УРЗН», канд. мед. наук.
ул. Монастырская, 82, Пермь, 614045
Е. М. Власова
Россия
Власова Елена Михайловна, зав. профцентром ФБУН «ФНЦ МПТ УРЗН», канд. мед. наук
ул. Монастырская, 82, Пермь, 614045
А. С. Байдина
Россия
Байдина Анастасия Сергеевна, врач-кардиолог ФБУН «ФНЦ МПТ УРЗН», канд. мед. наук
ул. Монастырская, 82, Пермь, 614045
В. Б. Алексеев
Россия
Алексеев Вадим Борисович, дир. ФБУН «ФНЦ МПТ УРЗН», д-р мед. наук
ул. Монастырская, 82, Пермь, 614045
Список литературы
1. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рабочая группа по лечению артериальной гипертонии Европейского Общества Гипертонии и Европейского Общества Кардиологов. Росс. кардиологический ж-л. 2014; 105 (1): 7–94.
2. Mancia G., Bertinieri G., Grassi G., Parati G., Pomidossi G., Ferrari A., et al. Effects of blood pressure measurement by the doctor on patients blood pressure and heart rate. Lancet. 1983; 2: 695–8 DOI:10.1016/S0140–6736(83)92244–4
3. Mancia G., Bombelli M., Seravalle M., Grassi G. Diagnosis and management of patients with white- coat and masked hypertension. Nat. Rev. Cardiol. 2011; 8: 686–93 DOI:10.1038/nrcardio.2011.115
4. Pickering T.G., James G.D., Boddie C., Harshfield G.A., Blank S., Laragh J.H. How common is white coat hypertension? JAMA. 1988; 259: 225–28 DOI:10.1001/jama.259.2.225
5. Franklin S.S., Thijs L., Hansen T.W. O’Brien Е., Staessen J.A. White-Coat Hypertension. New Insights From Recent Studies. Hypertension. 2013; 62: 982–7 DOI:10.1161/hypertensionaha.113.01275
6. O’Brien E., Parati G., Stergiou G., Asmar R., Beilin L., Bilo G. et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J. Hypertens. 2013; 31(9): 1731–68 DOI:10.1097/HJH.0b013e328363e964
7. Fagard Rh., Cornelissen V.A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J. Hypertens. 2007; 25: 2193–8 DOI:10.1097/hjh.0b013e3282ef6185
8. Thijs L., Staessen J., O’Brien E., Amery A., Atkins N., Baumgart P. et al. The ambulatory blood pressurein normotensiveand hypertensive subjects: resultsfrom an international database. Neth J Med. 1995; 46(2): 106–14 DOI:10.1016/0300–2977(94)00057-g
9. Lovibond K., JowettS., Barton P., Caulfi eld M., Heneghan C., Hobbs F.D. et al. Cost-eff ectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011; 378: 1219–30 DOI:10.1016/s0140–6736(11)61184–7
10. Watson R.D., Lumb R., Young M.A., Stallard T.J., Davies P., Littler W.A. Variation in cuffblood pressure in untreated outpatients with mild hypertension — implications for initiating antihypertensive treatment. J. Hypertens. 1987; 5: 207–21 DOI:10.1097/00004872–198704000–00012
11. Colloca L., Finniss D. Nocebo effects, patient-clinician communication, and therapeuticoutcomes. JAMA. 2012; 307: 567–8 DOI:10.1001/jama.2012.115
12. Mancia G. Clinical significance of white-coat hypertension. J. Hypertens. 2016; 34: 623–6 DOI:10.1097/hjh.0000000000000879
13. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Sacchi N. et al. Identifi cation of subjects with white-coat hypertension and persistently normal ambulatory blood pressure. Blood Press Monit. 1996; 1: 217–22.
14. Kikuya M., Hansen T.W., Thijs L., Björklund-Bodegård K., Kuznetsova T., Ohkubo T. et al. International Database on Ambulatoryblood pressure monitoring in relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007; 115: 2145–52 DOI:10.1161/circulationaha.106.662254
15. de la Sierra A., Banegas J.R., Oliveras A., Gorostidi M., Segura J., de la Cruz J.J. et al. Clinical differences between resistant hypertensives and patients treated and controlled with three of less drugs. J. Hypertens. 2012; 30: 1211–1216 DOI:10.1097/HJH.0b013e328353634e
16. de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P. et al. Clinical features of 8295 patients with resistant hypertension classifi ed on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898–902 DOI:10.1161/hypertensionaha.110.168948
17. Grassi G., Esler M. How to assess sympathetic activity in humans. J. Hypertens. 1999; 17: 719–34 DOI:10.1097/00004872–199917060–00001
18. Grassi G., Turri C., Vailati S., Dell’Oro R., Mancia G. Muscle and skin sympathetic nerve traffic during the white-coat effect. Circulation. 1999; 100: 222–5 DOI:10.1161/01.cir.100.3.222
19. Ogedegbe G., Pickering T.G., Clemow L., Chaplin W., Spruill T.M., Albanese G.M. The misdiagnosis of hypertension: the role of patient anxiety. Arch. Intern. Med. 2008; 168: 2459–65 DOI:10.1001/archinte.168.22.2459
20. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009; 54: 690–7 DOI:10.1161/hypertensionaha.108.119883
21. Smith P.A., Graham L.N., Mackintosh A.F., Stoker J.B., Mary D.A. Relationship between central sympathetic activity and stages of human hypertension. Am. J. Hypertens. 2004; 17: 217–22 DOI:10.1016/j.amjhyper.2003.10.010
22. Curgunlu A., Uzun H., Bavunoğlu I., Karter Y., Genç H., Vehid S. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J. Hum. Hypertens. 2005; 19: 629–33 DOI:10.1038/sj.jhh.1001867
23. Franklin S.S., Th ijs L., Hansen T.W., Li Y., Boggia J., Kikuya M. et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012; 59: 564–71 DOI:10.1161/hypertensionaha.111.180653
24. Verdecchia P., Reboldi G.P., Angeli F., Schillaci G., Schwartz J.E., Pickering T.G. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005; 45: 203–8 DOI:10.1161/01.hyp.0000151623.49780.89
25. Pierdomenico S.D., Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am. J. Hypertens. 2011; 24: 52–8 DOI:10.1038/ajh.2010.203
26. Hänninen M.R., Niiranen T.J., Puukka P.J., Johansson J., Jula A.M. Prognostic significance of masked and white-coat hypertension in the general population: the Finn-Home Study. J. Hypertens. 2012; 30(4): 705–12 DOI:10.1097/hjh.0b013e328350a69b
27. Sipahioglu N.T., Sipahioglu F. Closer look at white-coat hypertension. World J. Methodol. 2014; 26: 144–50 DOI:10.5662/wjm.v4.i3.144
28. Mancia G., Bombelli M., Facchetti R., Madotto F., Quarti-Trevano F., Friz H.P. et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009; 54: 226–32 DOI:10.1161/hypertensionaha.109.129882
29. Gustavsen P.H., Hoegholm A., Bang L.E., Kristensen K.S. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J. Hum. Hypertens. 2003;17: 811–7 DOI:10.1038/sj.jhh.1001643
30. Stergiou G.S., Asayama K., Thijs L., Kollias A., Niiranen T.J., Hozawa A. et al. Prognosis of white-coat and masked hypertension: International Database of Home blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014; 63(4): 675–82 DOI:10.1161/HYPERTENSIONAHA.113.02741
31. Briasoulis A., Androulakis E., Palla M., Papageorgiou N., Tousoulis D. White-coathypertension and cardiovascular events: a meta-analysis. J. Hypertens. 2016; 34(4): 593–9 DOI:10.1097/hjh.0000000000000832
32. Huang Y., Huang W., Mai W., Cai X., An D., Liu Z. et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J of Hypertension. 2017; 35: 677–88 DOI:10.1097/hjh.0000000000001226
33. Cuspidi C., Rescaldani M., Tadic M., Sala C., Grassi G., Mancia G. White-coat hypertension, as defi ned by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J. Hypertens. 2015; 33(1): 24–32 DOI:10.1097/hjh.000000000000041
34. Muscholl M.W., Hense H.W., Bröckel U., Döring A., Riegger G.A., Schunkert H. Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ. 1998; 317: 565–70 DOI:10.1136/bmj.317.7158.565
35. Owens P.E., Lyons S.P., Rodriguez S.A., O’Brien E.T. Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? J. Hum. Hypertens. 1998; 12: 743–8 DOI:10.1038/sj.jhh.1000721
36. Cuspidi C., Sala C., Tadic M., Rescaldani M., Grassi G., Mancia G. Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. Blood. Press. Monit. 2015; 20(2): 57–63 DOI:10.1097/MBP.0000000000000094
37. Hara A., Ohkubo T., Kikuya M., Shintani Y., Obara T., Metoki H. et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: the Ohasama study. J. Hypertens. 2007; 25: 321–7 DOI:10.1097/hjh.0b013e3280115bbf
38. Puato M., Palatini P., Zanardo M., Dorigatti F., Tirrito C., Rattazzi M. et al. Increase in carotid intima-media thickness in grade I hypertensive subjects: white-coat versus sustained hypertension. Hypertension. 2008; 51: 1300–5 DOI:10.1161/hypertensionaha.107.106773
39. Wimmer N.J., Sathi K., Chen T.L., Townsend R.R., Cohen D.L. Comparison of pulse wave analysis between persons with white coat hypertension and normotensive persons. J. Clin. Hypertens. 2007; 9: 513–7 DOI:10.1111/j.1524–6175.2007.06553.x
40. Karter Y., Aydin S., Curgunlu A., Uzun H., Ertürk N., Vehid S. et al. Endothelium and angiogenesis in white coat hypertension. J. Hum. Hypertens. 2004; 18: 809–14 DOI:10.1038/sj.jhh.1001752
41. Guven A., Tolun F., Caliskan M. C-reactive protein and nitric oxide level in patients with white coat hypertension. Blood Press. 2012; 21: 281–5 DOI:10.3109/08037051.2011.649541
42. Cloutier L., Daskalopoulou S.S., Padwal R.S., Lamarre-Cliche M., Bolli P., McLean D. et al. A New Algorithmfor the Diagnosisof Hypertensionin Canada. Can. J. Cardiol. 2015; 31(5): 620–30 DOI:10.1016/j.cjca.2015.02.014
43. Myers M.G., Valdivieso M., Kiss A. Use of automated pressure measurement to reduce the white coat response. J. Hypertens. 2009; 27: 280–6 DOI:10.1097/hjh.0b013e32831b9e6b
44. Цфасман А.З. Профессия и гипертония. М., 2012: 192.
Дополнительные файлы
Для цитирования: Носов А.Е., Власова Е.М., Байдина А.С., Алексеев В.Б. Изолированная офисная гипертония (гипертония «белого халата») в клинике Медицины труда (аналитический обзор). Медицина труда и промышленная экология. 2018;(10):33-38. https://doi.org/10.31089/1026-9428-2018-10-33-38
For citation: Nosov A.E., Vlasova E.M., Baydina A.S., Alekseev V.B. Isolated office hypertension («White coat» hypertension) in occupational medicine (analytic review). Occupational Health and Industrial Ecology. 2018;(10):33-38. (In Russ.) https://doi.org/10.31089/1026-9428-2018-10-33-38
Обратные ссылки
- Обратные ссылки не определены.
